Clinicians have found help from a new mobile app to gauge risks of coronary events in patients with heart disease, guiding them in designing treatment plans. AstraZeneca ($AZN) backed development of the app and has sponsored the software tool, PMLiVE's Dominic Tyer reported.
The GRACE 2.0 app, which is available for mobile devices that use Apple's ($APPL) iOS and Google's ($GOOG) Android operating systems, taps data from the Global Registry of Coronary Events (GRACE). The international database contains information on more than 102,000 patients from 30 countries and is intended to track outcomes of patients with acute coronary syndromes, according to its website.
London-based AstraZeneca is among many pharma groups that support or sponsor apps for clinicians as part of their digital efforts. The drugmaker supported work on the app, which was developed at the University of Edinburgh in Scotland and the University of Massachusetts. As PMLiVE noted, AZ has a stake in the heart disease market because of its drug Brilique and other products.
"One in five patients is likely to die within five years of their initial heart attack," said Professor Keith Fox, the app's lead developer from the University of Edinburgh, as quoted by PMLiVE. "Identifying those most at risk of a repeat heart attack means we can better tailor treatments to the individual and prevent further attacks."